Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status
- PMID: 29487977
- DOI: 10.1007/s00259-018-3969-4
Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status
Erratum in
-
Correction to: Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1078. doi: 10.1007/s00259-018-3991-6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29541813
Abstract
Purpose: For the clinical evaluation of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET images, the use of standard summation images obtained 20-40 min after injection is recommended. However, early summation images obtained 5-15 min after injection have been reported to allow better differentiation between low-grade glioma (LGG) and high-grade glioma (HGG) by capturing the early 18F-FET uptake peak specific for HGG. We compared early and standard summation images with regard to delineation of the PET-derived biological tumour volume (BTV) in correlation with the molecular genetic profile according the updated 2016 WHO classification.
Methods: The analysis included 245 patients with newly diagnosed, histologically verified glioma and a positive 18F-FET PET scan prior to any further treatment. BTVs were delineated during the early 5-15 min and standard 20-40 min time frames using a threshold of 1.6 × background activity and were compared intraindividually. Volume differences between early and late summation images of >20% were considered significant and were correlated with WHO grade and the molecular genetic profile (IDH mutation and 1p/19q codeletion status).
Results: In 52.2% of the patients (128/245), a significant difference in BTV of >20% between early and standard summation images was found. While 44.3% of WHO grade II gliomas (31 of 70) showed a significantly smaller BTV in the early summation images, 35.0% of WHO grade III gliomas (28/80) and 37.9% of WHO grade IV gliomas (36/95) had a significantly larger BTVs. Among IDH-wildtype gliomas, an even higher portion (44.4%, 67/151) showed significantly larger BTVs in the early summation images, which was observed in 5.3% (5/94) of IDH-mutant gliomas only: most of the latter had significantly smaller BTVs in the early summation images, i.e. 51.2% of IDH-mutant gliomas without 1p/19q codeletion (21/41) and 39.6% with 1p/19q codeletion (21/53).
Conclusion: BTVs delineated in early and standard summation images differed significantly in more than half of gliomas. While the standard summation images seem appropriate for delineation of LGG as well as IDH-mutant gliomas, a remarkably high percentage of HGG and, particularly, IDH-wildtype gliomas were depicted with significantly larger volumes in early summation images. This finding might be of interest for optimization of treatment planning (e.g. radiotherapy) in accordance with the individual IDH mutation status.
Keywords: 1p/19q codeletion; BTV; FET PET; Glioma; IDH.
Similar articles
-
Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.Eur Radiol. 2021 Jun;31(6):4087-4096. doi: 10.1007/s00330-020-07470-9. Epub 2020 Nov 19. Eur Radiol. 2021. PMID: 33211141
-
Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451. doi: 10.1007/s00259-017-3846-6. Epub 2017 Oct 17. Eur J Nucl Med Mol Imaging. 2018. PMID: 29043400
-
Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study.Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):580-590. doi: 10.1007/s00259-018-4166-1. Epub 2018 Sep 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 30244386
-
The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.Neurosurg Focus. 2019 Dec 1;47(6):E13. doi: 10.3171/2019.9.FOCUS19660. Neurosurg Focus. 2019. PMID: 31786548
-
Anaplastic gliomas in adults: an update.Curr Opin Oncol. 2017 Nov;29(6):434-442. doi: 10.1097/CCO.0000000000000409. Curr Opin Oncol. 2017. PMID: 28901965 Review.
Cited by
-
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study.Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):669-682. doi: 10.1007/s00259-024-06935-z. Epub 2024 Oct 4. Eur J Nucl Med Mol Imaging. 2025. PMID: 39365462
-
The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.BMC Cancer. 2021 Jan 20;21(1):83. doi: 10.1186/s12885-021-07797-6. BMC Cancer. 2021. PMID: 33472598 Free PMC article.
-
Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1).Molecules. 2024 Aug 21;29(16):3939. doi: 10.3390/molecules29163939. Molecules. 2024. PMID: 39203017 Free PMC article.
-
Assessment of Brain Tumour Perfusion Using Early-Phase 18F-FET PET: Comparison with Perfusion-Weighted MRI.Mol Imaging Biol. 2024 Feb;26(1):36-44. doi: 10.1007/s11307-023-01861-2. Epub 2023 Oct 17. Mol Imaging Biol. 2024. PMID: 37848641 Free PMC article.
-
TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas.Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):859-869. doi: 10.1007/s00259-022-06006-1. Epub 2022 Nov 4. Eur J Nucl Med Mol Imaging. 2023. PMID: 36329288 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical